Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Kate Young"'
Publikováno v:
Endocrine Connections. 12
Checkpoint inhibitors are now widely used in the management of many cancers. Endocrine toxicity is amongst the most common side effects. These endocrinopathies differ from most other immune-related toxicities in frequently being irreversible and rare
Autor:
Kaenat Mulla, Sheima Farag, Benedict Moore, Sheila Matharu, Kate Young, James Larkin, Sanjay Popat, Daniel Laurence Morganstein
Aims We systematically studied the presence of hyperglycaemia during treatment with Immune Checkpoint Inhibitors (ICPI) for cancer, in those with and without diabetes at baseline, and determined the cause of new-onset hyperglycaemia, Methods Retrospe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d230f6aec5cb141ec8973b8f9d18d46d
http://hdl.handle.net/10044/1/102827
http://hdl.handle.net/10044/1/102827
Publikováno v:
Clinical Drug Investigation
Background and Objective Omadacycline is an aminomethylcycline antibiotic approved in the USA as once-daily intravenous/oral monotherapy for adults with community-acquired bacterial pneumonia (CABP). Omadacycline demonstrated noninferiority to the fl
Autor:
Camille L. Gerard, Eleanor Carlyle, Karolina Rzeniewicz, Robert Wilkinson, William Gordon, Scott Thomas Colville Shepherd, Kate Young, Lewis Au, Kim Edmonds, Samra Turajlic, Annika Fendler, Barry Ward, Ruth Harvey, Charlotte Fribbens, George Kassiotis, James E. Larkin, Winston A. Haynes, Katalin A. Wilkinson, Ian Chau, John Shon, Ben Shum, Charles Swanton, Lyra Del Rosario, Lisa Pickering, Naureen Starling, Andrew James Scott Furness, David K. Lau, Fiona Byrne, Nalinie Joharatnam-Hogan, Sonia Gandhi, Maddalena Cerrone, Wenyi Xie
We present a case of cytokine release syndrome (CRS) that occurred five days after vaccination with BTN162b2 (tozinameran), an mRNA COVID-19 vaccine, in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57105d97d18e7c9d9fc7b6d8c06d6c7c
https://doi.org/10.21203/rs.3.rs-355230/v1
https://doi.org/10.21203/rs.3.rs-355230/v1
Autor:
Nicholas van As, Bram Snijders, Scott Thomas Colville Shepherd, Steve Gamblin, Kate Young, Adrian Hayday, James Larkin, Ben Shum, Laura Amanda Boos, Phillip Hobson, Tim Slattery, Georgina H. Cornish, Ana Agua-Doce, Olivia Curtis, Joanne Droney, Mike Gavrielides, Alison Reid, Helen R. Flynn, Katalin A. Wilkinson, Anthony J. Swerdlow, James I. MacRae, Susana Banerjee, Lewis Au, Shreerang Bhide, Michael Howell, Martin Pule, Nicholas C. Turner, Robin L. Jones, Fiona Byrne, Spyridon Gennatas, Christina Messiou, Richard Stone, Liam Welsh, Yasir Khan, Zayd Tippu, Firza Gronthoud, Camilla Gomes, Ruth Harvey, Naureen Starling, Maddalena Cerrone, Sacheen Kumar, Wenyi Xie, Barry Ward, Alicia Okines, Kevin J. Harrington, George Kassiotis, Nadia Yousaf, Annika Fendler, Kevin W. Ng, Kate Tatham, Jerome Nicod, Emma Nye, Andrew Furness, Shaman Jhanji, Simon Caidan, David Cunningham, Leila Mekkaoui, Samra Turajlic, Charles Swanton, Camille L. Gerard, Robert L. Goldstone, Ian Chau, Jennifer Rusby, Emma Nicholson, Isla Leslie, Robert J. Wilkinson, Lisa Pickering, Sonia Ghandi
SUMMARYThere is a pressing need to characterise the nature, extent and duration of immune response to SARS-CoV-2 in cancer patients and inform risk-reduction strategies and preserve cancer outcomes. CAPTURE is a prospective, longitudinal cohort study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9a28e61a8bd5ee40901ca8448ca9db7
https://doi.org/10.1101/2020.12.21.20248608
https://doi.org/10.1101/2020.12.21.20248608
Autor:
Meena Venkatachalam, Kate Young, James W. Shaw, Beata Korytowsky, Robert I. Haddad, Pranav Abraham, Ezra E.W. Cohen, Prianka Singh, Kevin J. Harrington
Publikováno v:
Journal of medical economics. 23(5)
Aim: To assess the cost-effectiveness of nivolumab monotherapy for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the US. Methods: We constructed a cohort-based partitioned survival model for three health states (p
Autor:
Jessica R. May, Derek H. Tang, Dinesh Mishra, Gary M. Oderda, Rohit Mistry, S Bhattacharyya, Devarshi Bhattacharyya, Kate Young, Gaurav Suri, Anand A. Dalal, Joseph Biskupiak, Robert Hettle, Diana I. Brixner
Publikováno v:
Current Medical Research and Opinion. 34:2143-2150
The combination of a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor with the aromatase inhibitor letrozole is a safe and effective alternative to letrozole monotherapy for first-line hormone receptor-positive (HR+)/human epidermal growth factor
Autor:
Kate Young, Eitan Friedman
Publikováno v:
Cureus
Eighty-five percent of all lung cancers are Non-Small-Cell Lung Carcinoma (NSCLC) with common sites of metastasis to the adrenal glands and liver. Onset is insidious, and seventy-five percent of patients have either regional or distant metastases at
Publikováno v:
Epilepsia. 58:e152-e156
We examined cognition in aging persons with chronic epilepsy; characterized targeted vascular, inflammatory, and metabolic risk factors associated with abnormal cognitive aging in the general population; and examined associations between cognition an
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 9 (2019)
Frontiers in Oncology, Vol 9 (2019)
In 2014, the survival benefits seen in REGARD and RAINBOW studies led the way for the regulatory approval of ramucirumab in the second line setting in oesophagogastric (OG) cancer. Trials of other drugs targeting the vascular endothelial growth facto